Annals of Oncology Advance Access originally published online on August 5, 2008
Annals of Oncology 2009 20(1):121-128; doi:10.1093/annonc/mdn551
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
hematologic malignancies |
Effective second-line chemotherapy for extranodal NK/T-cell lymphoma consisting of etoposide, ifosfamide, methotrexate, and prednisolone
1 Department of Internal Medicine, Seoul Municipal Boramae Hospital, Seoul
2 Department of Internal Medicine, Seoul
3 Department of Pathology, Seoul National University Hospital, Seoul
4 Department of Internal Medicine, Cancer Research Institute, Seoul National University College of Medicine, Seoul
5 Department of Internal Medicine, Center for Gastric Cancer, National Cancer Center Hospital, Goyang-si, Gyeonggi-do, South Korea
* Correspondence to: Prof. D. S. Heo, Department of Internal Medicine, Seoul National University College of Medicine, 28 Yongon-dong, Chongno-gu, Seoul, 110-744, South Korea. Tel: +82-2-2072-2857; Fax: +82-2-742-6689; E-mail: heo1013{at}snu.ac.kr
Background: Many patients with extranodal natural killer/T-cell lymphoma (NTCL) fail to the front-line therapy and need an effective second-line chemotherapy.
Patients and methods: This was single-institutional, phase II study. The primary end point was response rate and secondary end points were toxicity, time to treatment failure (TTF), and overall survival (OS). Patients with relapsed or refractory NTCL were eligible. They received the chemotherapy consisting of ifosfamide, methotrexate, etoposide, and prednisolone and it was repeated every 3 weeks.
Results: Thirty-two patients were enrolled and 15 patients had achieved partial remission (PR) or complete remission (CR) after the front-line chemotherapy. The International Prognostic Index scores were 0–1 in thirteen, 2 in five, 3 in five, and 4–5 in nine patients. Twelve and two patients achieved CR and PR, respectively. Median OS and TTF of all patients were 8.2 and 3.7 months, respectively. Non-hematologic toxic effects were well tolerated, but grade 3/4 leukopenia occurred in 11.7% of all cycles. Four patients developed febrile neutropenia and one patient died due to pneumonia.
Conclusions: This chemotherapy regimen was moderately effective for relapsed/refractory extranodal NTCL, nasal type. Toxic effects were moderate, but caution should be exercised to prevent severe infection.
Key words: NK/T-cell lymphoma, salvage chemotherapy, second-line chemotherapy
Received for publication January 6, 2008. Revision received June 30, 2008. Accepted for publication July 9, 2008.
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  M. Yamaguchi, K. Tobinai, M. Oguchi, N. Ishizuka, Y. Kobayashi, Y. Isobe, K. Ishizawa, N. Maseki, K. Itoh, N. Usui, et al. Phase I/II Study of Concurrent Chemoradiotherapy for Localized Nasal Natural Killer/T-Cell Lymphoma: Japan Clinical Oncology Group Study JCOG0211 J. Clin. Oncol., November 20, 2009; 27(33): 5594 - 5600. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. J. Kim, S. Y. Oh, J. Y. Hong, M. H. Chang, D. H. Lee, J. Huh, Y. H. Ko, Y. C. Ahn, H.-J. Kim, C. Suh, et al. When do we need central nervous system prophylaxis in patients with extranodal NK/T-cell lymphoma, nasal type? Ann. Onc., October 22, 2009; (2009) mdp412v1. [Abstract] [Full Text] [PDF]
|
|